FFR-Guided ACS Revascularization Apparently Superior to Culprit Vessel Treatment

Using fractional flow reserve (FFR) to guide revascularization of all functionally significant lesions in the setting of acute coronary syndrome appears to improve outcomes over treating only the culprit artery, according to the Compare-Acute trial.   This study, conducted at 24 centers in Europe and Asia, enrolled 885 patients who were stable following successful primary angioplasty and<a href="https://solaci.org/en/2017/04/11/ffr-guided-acs-revascularization-apparently-superior-to-culprit-vessel-treatment/" title="Read more" >...</a>

SYNERGY vs. XIENCE in Complex Real-World Patients

Courtesy of Dr. Guillermo Migliaro. Technological advancements in drug-eluting stents (DES) have shown significant improvement as regards the safety and efficacy of these devices. DES are considered to be the golden standard for the treatment of percutaneous coronary interventions.   DES with permanent or durable polymers (DP) have been associated with local inflammatory reactions and<a href="https://solaci.org/en/2017/04/01/synergy-vs-xience-in-complex-real-world-patients/" title="Read more" >...</a>

angioplastia en centros sin apoyo quirúrgico

Is Angioplasty at Centers Without Surgical Backup Safe?

Performing coronary angioplasties at hospitals without surgical backup seems to be safe for a wide variety of patients, from those presenting ST-segment elevation myocardial infarction to those undergoing elective procedures.   This work responds to a long-running debate over whether centers without on-site surgery capabilities in case of complications can be considered as referral centers<a href="https://solaci.org/en/2016/12/01/is-angioplasty-at-centers-without-surgical-backup-safe/" title="Read more" >...</a>

Trombos residuales angioplastia primaria

Residual Thrombus After Aspiration Thrombectomy: Does It Affect the Outcome of Primary Angioplasty?

The aim of this study was to evaluate if the residual thrombus burden after aspiration thrombectomy may affect the outcome of primary angioplasty in patients with acute coronary syndrome with ST-segment elevation.   The most recent studies on aspiration thrombectomy failed to show clinical benefit in patients with ST-segment elevation. This study is based on<a href="https://solaci.org/en/2016/10/20/residual-thrombus-after-aspiration-thrombectomy-does-it-affect-the-outcome-of-primary-angioplasty/" title="Read more" >...</a>

Dual Antiplatelet Therapy in Men and Women: Are There Differences?

Courtesy of Dr. Agustín Vecchia.   Currently, the duration of dual antiplatelet therapy (DAPT) after stent placement is one of the most highly debated topics in Cardiology. On the one hand, women are usually underrepresented in trials in our specialty; on the other, the fact that symptoms of coronary disease are different in women is well-known.   The aim<a href="https://solaci.org/en/2016/09/12/dual-antiplatelet-therapy-in-men-and-women-are-there-differences/" title="Read more" >...</a>

ABSORV at Long Term in Daily Practice Lesions

This work reports one year outcomes of the BVS Expand registry. Multiple studies have shown the safety and feasibility of the everolimus eluting bioresorbable scaffold ABSORB (Abbott Vascular, Santa Clara, California), but medium and long term data are limited and only on simple lesions.   This is a prospective single-center registry assessing ABSORB performance in<a href="https://solaci.org/en/2016/08/24/absorv-at-long-term-in-daily-practice-lesions/" title="Read more" >...</a>

BVS: Comparable to Second-Generation DES in Complex Lesions

A center carrying out a mid- to long-term follow-up of the performance of everolimus-eluting bioresorbable scaffolds (Absorb) observed that this new device has an acceptable rate of major cardiovascular events, when compared to second-generation drug-eluting stents. Furthermore, although the population was complex and non-selected, no cases of early thrombosis were reported. This study enrolled 249 patients<a href="https://solaci.org/en/2016/08/03/bvs-comparable-to-second-generation-des-in-complex-lesions/" title="Read more" >...</a>

STEMI: Best P2Y12 inhibitor according to network meta-analysis

Original Title: Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a network meta-analysis. Reference: Rafique AM et al. J Am Coll Cardiol Intv 2016;9:1036–46.   Courtesy of Dr. Alejandro Lakowsky.     Researchers drew up a network meta-analysis incorporating 37 trials with more than 88,000 patients undergoing ST elevation<a href="https://solaci.org/en/2016/06/22/stemi-best-p2y12-inhibitor-according-to-network-meta-analysis/" title="Read more" >...</a>

Immediate vs. Delayed Stenting in Primary PCI

Original Title: Comparison of Immediate With Delayed Stenting Using the Minimalist Immediate Mechanical Intervention Approach in Acute ST-Segment–Elevation Myocardial Infarction. The MIMI Study. Reference: Loic Belle et al. Circ Cardiovasc Interv. 2016 Mar;9(3).   Delayed stenting after normal epicardial flow restoration is meant to lower the chance of distal embolization and to improve reperfusion in the<a href="https://solaci.org/en/2016/03/30/immediate-vs-delayed-stenting-in-primary-pci/" title="Read more" >...</a>

IMPROVE-IT: The combination simvastatin / ezetimibe reduces post SCA events

This work included 18144 patients from 39 countries that were admitted pursuing an acute coronary syndrome (with or without ST segment elevation) randomized 1: 1 to receive the combination of simvastatin 40 mg / ezetimibe 10 mg (n = 9067) or simvastatin 40 mg alone (n = 9077). Of the total, 88% received a coronary<a href="https://solaci.org/en/2015/06/24/improve-it-the-combination-simvastatin-ezetimibe-reduces-post-sca-events/" title="Read more" >...</a>

acute myocardial infarction